Depressive Disorders in Children and Adolescents
Definition and Core Clinical Features
- Depression in the pediatric population is characterized by a persistent sad or irritable mood that causes significant impairment in functioning at home, school, or work.
- The clinical presentation often varies by developmental stage; young children frequently present with prominent irritability and somatic complaints, whereas adolescents more commonly exhibit disturbances in energy, activity level, appetite, and sleep.
- Because of cognitive and linguistic immaturity, symptoms of depression in young children are often observed by caregivers rather than self-reported.
The SIGECAPS Mnemonic for Depressive Symptoms
| Letter | Symptom Domain | Clinical Manifestation |
|---|---|---|
| S | Sleep disorder | Insomnia or hypersomnia. |
| I | Interest deficit | Anhedonia (diminished interest or pleasure in activities). |
| G | Guilt | Excessive feelings of worthlessness, hopelessness, or regret. |
| E | Energy deficit | Fatigue or loss of energy nearly every day. |
| C | Concentration deficit | Diminished ability to think, concentrate, or make decisions. |
| A | Appetite disorder | Significant weight loss/gain, or increased/decreased appetite. |
| P | Psychomotor | Observable psychomotor retardation or agitation. |
| S | Suicidality | Recurrent thoughts of death, suicidal ideation, or suicide attempts. |
DSM-5 Diagnostic Criteria for Major Depressive Episode
- The diagnosis requires the presence of five (or more) specific symptoms during the same 2-week period, representing a clear change from previous functioning.
- At least one of the symptoms must be either a depressed/irritable mood or a loss of interest/pleasure.
- For children and adolescents, the mood can specifically be irritable rather than purely depressed.
- When assessing weight criteria in pediatric patients, clinicians must consider a failure to make expected weight gain, rather than strict weight loss.
- The symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning and must not be attributable to the physiologic effects of a substance or another medical condition.
Etiology and Risk Factors
- The etiology incorporates both genetic and environmental pathways, with monozygotic twin studies showing concordance rates of 40% to 65%.
- Biologic vulnerabilities include abnormalities in the hypothalamic-pituitary-adrenal axis, serotonergic dysfunction, and cerebral variations in structure and function.
- Environmental risk factors are highly predictive and include physical or sexual abuse, neglect, chronic illness, social isolation, bullying, academic failure, and family or marital disharmony.
- Parental psychopathology, particularly a bidirectional increase in depression among first-degree relatives, is a significant risk factor.
Screening and Differential Diagnosis
- The differential diagnosis is broad and includes adjustment disorder, bipolar disorder, disruptive mood dysregulation disorder, and substance-induced mood disorder.
- Medical conditions that can mimic depression, such as hypothyroidism, anemia, autoimmune disorders, and chronic infections, must be ruled out with targeted diagnostic tests (e.g., thyroid profile, complete blood cell count).
- It is critical to screen for manic or hypomanic symptoms before diagnosing unipolar depression, as treating a bipolar patient with antidepressants can trigger an iatrogenic manic episode.
| Common Pediatric Depression Screening Tools | Target Age Range | Informant |
|---|---|---|
| Center for Epidemiologic Studies-Depression-Children (CES-DC) | 6โ18 years | Child. |
| Children's Depression Rating Scale-Revised | 6โ18 years | Youth, Parent, Clinician. |
| Mood and Feelings Questionnaire (MFQ) | 7โ18 years | Youth, Parent. |
| Patient Health Questionnaire-9 (PHQ-9) | 12/13+ years | Youth. |
Management Principles
- The treatment of pediatric depression typically utilizes psychotherapy, medication management, or a combination of the two, with combination therapy often yielding the most positive response rates.
- Mild Depression: In the absence of major risk factors (e.g., suicidality or psychosis), initial management involves guided self-help, watchful waiting, sleep hygiene optimization, physical exercise, and supportive therapy.
- Psychotherapy: Cognitive Behavioral Therapy (CBT) is highly effective and focuses on identifying and correcting cognitive distortions while teaching behavior activation, problem-solving, and emotional regulation. Interpersonal Therapy (IPT) is also utilized to resolve interpersonal conflicts and enhance social communication.
- Pharmacotherapy (SSRIs):
- Selective Serotonin Reuptake Inhibitors (SSRIs) are the only class of medications currently approved by the U.S. Food and Drug Administration (FDA) for major depressive disorder in children.
- Fluoxetine is the antidepressant of choice and is approved for children 8 years and older; escitalopram is approved for adolescents 12 years and older.
- Medication should be initiated at the lowest effective dose (e.g., 5 or 10 mg of fluoxetine) and titrated slowly.
- Black Box Warning: All antidepressants carry an FDA warning regarding an increased risk of suicidal thinking and behavior in children, adolescents, and young adults under 25 years of age.
- Patients require rigorous monitoring: weekly evaluations for the first 4 weeks of treatment, followed by twice-monthly visits for weeks 4 through 8.
- Common adverse effects include gastrointestinal upset, headaches, insomnia, and akathisia (an uncomfortable feeling of internal restlessness, which is more common in children than adults). Behavioral activation or disinhibition can also occur, requiring dose reduction or discontinuation.